Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Q-1802 Combined with XELOX in Gastrointestinal Tumors
NCT05964543Phase 2Unknown
- Sponsor
- QureBio Ltd.
- Start
- Jun 2023
- Primary completion
- Aug 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of q-1802 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by QureBio Ltd. Primary endpoints: Number of participants with treatment-related adverse events up to 12 months and Objective Response Rate up to 6 months. Status: unknown.
02
Drugs
q-1802
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05964543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05964543.